Shotgun brain proteomics reveals early molecular signature in presymptomatic mouse model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 37, Issue 2, 2013, Pages 297-308

  Yang, Hongqian ^a   Wittnam, Jessica L ^b   Zubarev, Roman A ^a,c   Bayer, Thomas A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

Amyloid peptide; LC MS; mass spectrometry; shotgun proteomics

Indexed keywords

APOLIPOPROTEIN B; GUANOSINE TRIPHOSPHATASE; INOSITOL TRISPHOSPHATE 3 KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN HOMER; PROTEIN SERINE THREONINE KINASE; RHO KINASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASYMPTOMATIC DISEASE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL ADHESION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; MASS SPECTROMETRY; MOLECULAR PATHOLOGY; MOUSE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEOMICS; SHOTGUN BRAIN PROTEOMICS; STATISTICAL SIGNIFICANCE; SYNAPSE; TRANSGENIC MOUSE; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELL ADHESION MOLECULES, NEURONAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRINCIPAL COMPONENT ANALYSIS; PROTEIN INTERACTION MAPPING; PROTEOMICS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; THYROTROPIN-RELEASING HORMONE;

EID: 84883782212     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130476     Document Type: Article

References (71)

1. Selkoe DJ (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8, 447-453.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297, 353-356.
3. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249.
4. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K (1993) Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301, 41-52.
5. Prelli F, Castano E, Glenner GG, Frangione B (1988) Differences between vascular and plaque core amyloid in Alzheimer's disease. J Neurochem 51, 648-651.
6. Jarrett JT, Berger EP, Lansbury PT (1993) The carboxy terminus of the beta-amyloid protein is critical for the seeding of amyloid formation - implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
7. Pike CJ, Cummings BJ, Cotman CW (1995) Early association of reactive astrocytes with senile plaques in Alzheimer's disease. Exp Neurol 132, 172-179.
8. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A-42(43) and A-40 in senile plaques with end-specific A- monoclonals: Evidence that an initially deposited species is A-42(43). Neuron 13, 45-53.
9. Barrow C, Zagorski M (1991) Solution structures of beta peptide and its constituent fragments: Relation to amyloid deposition. Science 253, 179-182.
10. Mori H, Takio K, Ogawara M, Selkoe D (1992) Massspectrometry of purified amyloid-beta protein in Alzheimer's disease. J Biol Chem 267, 17082-17086.
11. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct -amyloid peptide species, A-N3(pE), in senile plaques. Neuron 14, 457-466.
12. Harigaya Y, Saido TC, Eckman CB, Prada C-M, Shoji M, Younkin SG (2000) Amyloid - protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem Biophys Res Commun 276, 422-427.
13. Portelius E, Bogdanovic N, Gustavsson M, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol 120, 185-193.
14. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P, Schettini G (2002) Pyroglutamate-modified amyloid beta-peptides - A beta N3(pE)-strongly affect cultured neuron and astrocyte survival. J Neurochem 82, 1480-1489.
15. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, Funke SA, Schilling S, Demuth HU (2009) Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 48, 7072- 7078.
16. Kimpe L, Haastert E, Kaminari A, Zwart R, Rutjes H, Hoozemans JM, Scheper W (2012) Intracellular accumulation of aggregated pyroglutamate amyloid beta: Convergence of aging and A- pathology at the lysosome. Age 35, 673- 687.
17. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth H-U, Bloom GS (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-. Nature 485, 651-655.
18. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth H-U, Rossner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate A[beta] and Alzheimer's disease-like pathology. Nat Med 14, 1106- 1111.
19. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA (2009) Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 118, 487- 496.
20. Alexandru A, Jagla W, Graubner S, Becker A, Bäuscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, Rönicke R, Reymann KG, Petrasch-Parwez E, Hartlage-Rübsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth H-U, von Hörsten S (2011) Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A- is induced by pyroglutamate-A- formation. J Neurosci 31, 12790-12801.
21. Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth H-U, Blennow K, Wirths O, Bayer TA (2012) Pyroglutamate amyloid - (A-) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J Biol Chem 287, 8154- 8162.
22. Gillardon F, Rist W, Kussmaul L, Vogel J, Berg M, Danzer K, Kraut N, Hengerer B (2007) Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7, 605- 616.
23. Dencher NA, Frenzel M, Reifschneider NH, Sugawa M, Krause F (2007) Proteome alterations in rat mitochondria caused by aging. Ann N Y Acad Sci 1100, 291-298.
24. Robinson RAS, Lange MB, Sultana R, Galvan V, Fombonne J, Gorostiza O, Zhang J, Warrier G, Cai J, Pierce WM, Bredesen DE, Butterfield DA (2011) Differential expression and redox proteomics analyses of an Alzheimer disease transgenic mouse model: Effects of the amyloid- peptide of amyloid precursor protein. Neuroscience 177, 207-222.
25. Cisśe M, Sanchez PE, Kim DH, Ho K, Yu G-Q, Mucke L (2011) Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. J Neurosci 31, 10427-10431.
26. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A- and synaptic dysfunction. Neuron 39, 409-421.
27. Chou JL, ShenoyDV, Thomas N, Choudhary PK, LaFerla FM, Goodman SR, Breen GAM (2011) Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J Proteomics 74, 466-479.
28. Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee VM-Y (2011) Intraneuronal APP, not free A- peptides in 3xTg-AD mice: Implications for tau versus A-mediated Alzheimer neurodegeneration. J Neurosci 31, 7691-7699.
29. Wirths O, Dins A, Bayer TA (2012) A-PP accumulation and/or intraneuronal amyloid- accumulation? The 3xTg-AD mouse model revisited. J Alzheimers Dis 28, 897-904.
30. Sowell RA, Owen JB, Butterfield DA (2009) Proteomics in animal models of Alzheimer's and Parkinson's diseases. Ageing Res Rev 8, 1-17.
31. Scholz B, Sköld K, Kultima K, Fernandez C, Waldemarson S, Savitski MM, Söderquist M, Boŕen M, Stella R, Andŕen P, Zubarev R, James P (2011) Impact of temperature dependent sampling procedures in proteomics and peptidomics -Acharacterization of the liver and pancreas post mortem degradome. Mol Cell Proteomics 10, mcp.M900229-MCP200.
32. Fischer F, Wolters D, Rogner M, Poetsch A (2006) Toward the complete membrane proteome - High coverage of integral membrane proteins through transmembrane peptide detection. Mol Cell Proteomics 5, 444-453.
33. Wísniewski JR, Ostasiewicz P, MannM(2011) High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J Proteome Res 10, 3040-3049.
34. Zubarev RA, Nielsen ML, Fung EM, Savitski MM, Kel-Margoulis O, Wingender E, Kel A (2008) Identification of dominant signaling pathways from proteomics expression data. J Proteomics 71, 89-96.
35. St°ahl S, Fung E, Adams C, Lengqvist J, Mörk B, Stenerlöw B, Lewensohn R, Lehtiö J, Zubarev R, Viktorsson K (2009) Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. Mol Cell Proteomics 8, 1117-1129.
36. Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S (2011) Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol Cell Proteomics 10, mcp.M110.002980.
37. GoodDM,ZubarevRA(2011) Drug target identification from protein dynamics using quantitative pathway analysis. J Proteome Res 10, 2679-2683.
38. Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth H-U, Blennow K, Wirths O, Bayer TA (2012) Pyroglutamate A(beta) aggravates behavioral deficits in 5XFAD mice. J Biol Chem 287, 8154-8162.
39. Chauhan V, Sheikh AM, Chauhan A, Spivack WD, Malik MN (2005) Fibrillar amyloid beta-protein inhibits the activity of high molecular weight brain protease and trypsin. J Alzheimers Dis 7, 37-44.
40. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J Biol Chem 267, 17082-17086.
41. Rüfenacht P, Güntert A, Bohrmann B, Ducret A, Döbeli H (2005) Quantification of the A- peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J Mass Spect 40, 193-201.
42. Portelius E, Zetterberg H, Gobom J, Andreasson U, Blennow K (2008) Targeted proteomics in Alzheimer's disease: Focus on amyloid-beta. Expert Rev Proteomics 5, 225-237.
43. Fisher RA (1932) Statistical methods for research workers, Oliver and Boyd.
44. Gao J, Chen T, Liu J, Liu W, Hu G, Guo X, Yin B, Gong Y, Zhao J, Qiang B, Yuan J, Peng X (2009) Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. Glia 57, 989-999.
45. Worley PF, Zeng W, Huang G, Kim JY, Shin DM, Kim MS, Yuan JP, Kiselyov K, Muallem S (2007) Homer proteins in Ca2+ signaling by excitable and non-excitable cells. Cell Calcium 42, 363-371.
46. Parisiadou L, Bethani I, Michaki V, Krousti K, Rapti G, Efthimiopoulos S (2008) Homer2 and Homer3 interact with amyloid precursor protein and inhibit A- production. Neurobiol Dis 30, 353-364.
47. Potschka H, Krupp E, Ebert U, Gümbel C, Leichtlein C, Lorch B, Pickert A, Kramps S, Young K, Grüne U, Keller A, Welschof M, Vogt G, Xiao B, Worley PF, Löscher W, Hiemisch H (2002) Kindling-induced overexpression of Homer 1A and its functional implications for epileptogenesis. Eur J Neurosci 16, 2157-2165.
48. Windhorst S, Kalinina T, Schmid K, Blechner C, Kriebitzsch N, Hinsch R, Chang L, Herich L, Schumacher U, Mayr GW (2011) Functional role of inositol-1,4,5-trisphosphate-3-kinase-A for motility of malignant transformed cells. Int J Cancer 129, 1300-1309.
49. Kawahara M, Ohtsuka I, Yokoyama S, Kato-Negishi M, Sadakane Y (2011) Membrane incorporation, channel formation, and disruption of calcium homeostasis by Alzheimer's beta-amyloid protein. Int J Alzheimers Dis, 304583.
50. Cheung K-H, Shineman D, Müller M, Ćardenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VMY, Foskett JK (2008) Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 58, 871-883.
51. Salminen A, Suuronen T, Kaarniranta K (2008) ROCK, PAK, and Toll of synapses in Alzheimer's disease. Biochem Biophys Res Commun 371, 587-590.
52. Kubo T,Yamaguchi A, Iwata N,Yamashita T (2008) The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 4, 605-615.
53. Pei JJ, Hugon J (2008) mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med 12, 2525-2532.
54. Pei JJ, Bjorkdahl C, Zhang HY, Zhou XW,Winblad B (2008) p70 S6 kinase and tau in Alzheimer's disease. J Alzheimers Dis 14, 385-392.
55. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK (2010) Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS ONE 5, e12845.
56. Bhaskar K, Miller M, Chludzinski A, Herrup K, Zagorski M, Lamb B (2009) The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener 4, 14.
57. Takai Y, Miyoshi J, Ikeda W, Ogita H (2008) Nectins and nectin-like molecules: Roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 9, 603- 615.
58. Kakunaga S, Ikeda W, Itoh S, Deguchi-Tawarada M, Ohtsuka T, Mizoguchi A, Takai Y (2005) Nectin-like molecule-1/TSLL1/SynCAM3: A neural tissue-specific immunoglobulin-like cell-cell adhesion molecule localizing at non-junctional contact sites of presynaptic nerve terminals, axons and glia cell processes. J Cell Sci 118, 1267-1277.
59. Miyoshi J, Takai Y (2007) Nectin and nectin-like molecules: Biology and pathology. Am J Nephrol 27, 590-604.
60. Brouillette J, Young D, During MJ, Quirion R (2007) Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABAB receptors in scopolamine-induced amnesia. J Neurochem 102, 1978-1989.
61. Vanweyenberg V, Communi D, D'Santos CS, Erneux C (1995) Tissue- and cell-specific expression of Ins(1,4,5)P3 3-kinase isoenzymes. Biochem J 306, 429-435.
62. Xia HJ, Guang Y (2005) Inositol 1,4,5-trisphosphate 3-kinases: Functions and regulations. Cell Res 15, 83-91.
63. Kim IH, Park SK, Sun W, Kang Y, Kim HT, Kim H (2004) Spatial learning enhances the expression of inositol 1,4,5-trisphosphate 3-kinase A in the hippocampal formation of rat. Brain Res Mol Brain Res 124, 12-19.
64. Kim IH, Park SK, Hong ST, Jo YS, Kim EJ, Park EH, Han SB, Shin H-S, SunW, Kim HT, Soderling SH, Kim H (2009) Inositol 1,4,5-trisphosphate 3-kinase a functions as a scaffold for synaptic Rac signaling. J Neurosci 29, 14039-14049.
65. Windhorst S, Minge D, Bähring R, Hüser S, Schob C, Blechner C, Lin H-Y, Mayr GW, Kindler S (2012) Inositol-1,4,5-trisphosphate 3-kinase A regulates dendritic morphology and shapes synaptic Ca2+ transients. Cell Signal 24, 750-757.
66. Cheung KH, Shineman D, Muller M, Cardenas C, Mei LJ, Yang J, Tomita T, Iwatsubo T, Lee VMY, Foskett JK (2008) Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP(3) receptor channel gating. Neuron 58, 871-883.
67. Demuro A, Parker I, Stutzmann GE (2010) Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 285, 12463-12468.
68. Herskowitz JH, Seyfried NT, Gearing M, Kahn RA, Peng J, Levey AI, Lah JJ (2011) Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA alters amyloid-production. J Biol Chem 286, 6117-6127.
69. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME, Gandy S (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. Plos Med 2, 69-78.
70. Caccamo A, Maldonado MA, Majumder S, Medina DX, HolbeinW, MagŕiA, Oddo S (2011) Naturally secreted amyloid-increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem 286, 8924- 8932.
71. Lyutvinskiy Y, Yang H, Rutishauser D, Zubarev R (2013) In silico instrumental response correction improves precision of label-free proteomics and accuracy of proteomics-based predictive models. Mol Cell Proteomics, mcp.O112.023804.